Please enable Javascript to use all features and improve your user experience.
EHC 2024
Programme
Posters
Search
EN
All people
Patricia Pozo-Rosich
Sort by Type
Date
Chair
06.12.
09:00
–
10:30
Parallel session
Cluster headache – What's new?
Plenary hall
Invited speaker
Discussion
Panel discussion with all speakers
Speaker
ePoster
P168
Long-term sustained response of Atogepant in episodic and chronic migraine: an interim analysis of a phase 3, open-label, 156-week safety extension study
ePoster
P202
Long-term effectiveness of eptinezumab in patients with migraine and 2-4 prior preventive treatment failures who self-reported psychiatric comorbidities at screening
Further involvements
ePoster
P071
Contemporary prospective understanding of migraine real-world evidence (CAPTURE): baseline clinical characteristics
ePoster
P048
Effectiveness of onabotulinumtoxinA (BTX-A) and anti-calcitonin gene-related peptide (CGRP) antibodies in menstrual migraine
ePoster
P004
Anti-CGRP monoclonal antibodies treatment discontinuation in migraine: when and why
ePoster
P018
A multidisciplinary multicentric approach to the identification of BIOmarkers of MIGraine (BIOMIGA project): an open-label, prospective clinical study based on the stratification of responders to Erenumab
ePoster
P104
Exploring comorbidities in resistant and refractory migraine: results from the REFINE study
ePoster
P105
Multicenter study on the evolution of insomnia in patients with migraine treated with anti-CGRP: expanding the impact of new treatments
ePoster
P168
Long-term sustained response of Atogepant in episodic and chronic migraine: an interim analysis of a phase 3, open-label, 156-week safety extension study
ePoster
P095
A multidisciplinary multicentric approach to the identification of BIOmarkers of MIGraine (BIOMIGA project): an open-label, prospective biochemical study based on the stratification of responders to Erenumab
ePoster
P172
Differences in structural neuroimaging in migraine and healthy controls
ePoster
P110
Concomitant anti-CGRP drug and immunomodulator treatment in patients with autoimmune diseases: results of the multicenter "ImmunoCGRP" study on migraine
ePoster
P135
Characterization of migraine- and depressive-like symptoms in mice models of migraine and depression show significant sex differences
ePoster
P136
Olcegepant and fluoxetine modulate the development of migraine – and depressive-like symptoms in mice models of both disorders in a sex-dependent manner
ePoster
P153
A multidisciplinary multicentric approach to the identification of BIOmarkers of MIGraine (BIOMIGA project): DNA methylation patterns in migraine
ePoster
P180
Contemporary prospective understanding of migraine real-world evidence (CAPTURE): baseline patient-reported outcomes
ePoster
P183
Impact of Fremanezumab cessation and reinitiation in migraine management: PEARL study 4th interim analysis
ePoster
P202
Long-term effectiveness of eptinezumab in patients with migraine and 2-4 prior preventive treatment failures who self-reported psychiatric comorbidities at screening
ePoster
P203
Contemporary prospective understanding of migraine real-world evidence (CAPTURE): baseline migraine treatment patterns
ePoster
P209
Comparison of brain structural MRI before and after 6-months of preventive treatment with anti-CGRP monoclonal antibodies and onabotulinumtoxinA in people with migraine
ePoster
P192
Integrative analysis of omics markers associated with neuronal damage in migraine
ePoster
P193
Exploring the link between inhibitory cognitive control and sensory sensitivity in migraine – a case-control study
v1.20.0
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy